Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111954 | 0.86 | GAA (0.56) | HPGDSMAPTALPLNPC1RAB9A | |
| SCHEMBL6262942 | 0.83 | HCAR2 (0.54) | HPGDSTP53KMT2AMEN1KDM4E | |
| SCHEMBL3261535 | 0.83 | ALPL (0.54) | HPGDSMAPTTP53CASP3SENP8 | |
| SCHEMBL7901147 | 0.81 | MAPT (0.69) | HPGDSMAPTTP53CASP3SENP8 | |
| SCHEMBL17288834 | 0.81 | HPGDS (0.55) | HPGDSMAPTTP53CASP3SENP8 | |
| SCHEMBL25427728 | 0.79 | ALPL (0.46) | HPGDSMAPTALPLKMT2ANPC1 | |
| SCHEMBL29524545 | 0.79 | ALPL (0.46) | HPGDSMAPTALPLKMT2ANPC1 | |
| SCHEMBL25350380 | 0.79 | HPGDS (0.48) | HPGDSGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16112173 | 0.78 | HPGDS (0.59) | HPGDSGABRA1GABRA3MAPTTP53 | |
| SCHEMBL9199134 | 0.78 | MMP2 (0.51) | HPGDSMAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663189-A2 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-17 | — | — | EP | disclosed |
| EP-4116301-B1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20240417406-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-12-19 | — | — | US | disclosed |
| CN-115151543-B | Fused tricyclic compounds and medical uses thereof | 日本烟草产业株式会社 | 2024-12-17 | — | — | CN | disclosed |
| EP-4438040-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2024-10-02 | — | — | EP | disclosed |
| CN-117897382-A | Nitrogen-containing tricyclic compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023032940-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-03-09 | — | — | WO | disclosed |
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4116301-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116301-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2023-01-11 | — | — | EP | disclosed |
| CN-115151543-A | Fused tricyclic compounds and medical use thereof | 日本烟草产业株式会社 | 2022-10-04 | — | — | CN | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | PC, PCK2, AGK | HPGDS 1087/4885GABRA1 3790/4885GABRG2 3909/4885 |
| US-20240417406-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | PC, PCK2, AGK | HPGDS 1054/4885GABRA1 4497/4885GABRG2 4586/4885 |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | HPGDS 101/4885GABRA1 3275/4885GABRG2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.